| Serial Number | 90798006 |
| Word Mark | EMENDOBIO |
| Filing Date | Monday, June 28, 2021 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Wednesday, November 5, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 27, 2022 |
| Goods and Services | Enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research purposes; nucleases and nuclease panels derived from biotechnological processes for use in scientific and research purposes; assays and reagents for use in genetic research; nucleases and nuclease panels for use in genetic research |
| Goods and Services | Enzyme preparations for medical purposes; enzymes for medical purposes; nucleases and nuclease panels for medical purposes; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the prevention of diseases or decisions caused by genetic predispositions; pharmaceutical preparations for editing of faulty genes; chemical preparations for pharmaceutical or medical purposes, namely, for editing of faulty genes; anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; ocular pharmaceuticals; pharmaceutical preparations and substances for the treatment of genetic blood disorders |
| Goods and Services | Testing, research, or development of pharmaceutical preparations for gene therapy; testing, research, selection, optimization or development of nucleases for gene targeting, gene editing, or gene therapy; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; scientific research in the field of genetics, gene editing and genetic engineering; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific research consulting in the field of genetics; scientific research consulting in the field of gene editing; scientific research consulting in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; scientific research in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; pharmaceutical research services in the field of genetics and gene therapy, excluding production technologies; pharmaceutical research and development in the field of genetics and gene therapy, excluding production technologies; pharmaceutical products development in the field of genetics and gene therapy; pharmaceutical product evaluation in the field of genetics and gene therapy; pharmaceutical drug development services in the field of genetics and gene therapy, excluding production technologies; development of pharmaceutical preparations and medicines in the field of genetics and gene therapy; technical research in the field of pharmaceutical studies in the field of genetics and gene therapy, excluding production technologies; research and development in the pharmaceutical and biotechnology fields of genetics and gene therapy, excluding production technologies; testing of pharmaceuticals in the field of genetics and gene therapy; laboratory research services relating to pharmaceuticals in the field of genetics and gene therapy; conducting early evaluations in the field of new pharmaceuticals in the field of genetics and gene therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of genetics and gene therapy; medical research services in the field of genetics and gene therapy; medical research services in the field of genetic blood disorders; medical research services in the field of genetic ocular disorders; scientific research for medical purposes in the field of gene editing and genetic disorders; scientific research for medical purposes in the field of nuclease and nuclease panel discovery and optimization for the development of gene-targeting pharmaceuticals |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 10, 2021 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 10, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 10, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | EmendoBio Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10069 |
| Party Name | EmendoBio Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10069 |
| Event Date | Event Description |
| Thursday, July 1, 2021 | NEW APPLICATION ENTERED |
| Friday, September 10, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, March 18, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, May 3, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, May 3, 2022 | NON-FINAL ACTION E-MAILED |
| Tuesday, May 3, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, November 3, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, November 3, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, November 3, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, November 22, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 7, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 27, 2022 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 27, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 24, 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Monday, June 26, 2023 | OPPOSITION INSTITUTED NO. 999999 |
| Monday, March 10, 2025 | ASSIGNED TO EXAMINER |
| Monday, March 24, 2025 | OPPOSITION DISMISSED NO. 999999 |
| Monday, March 24, 2025 | OPPOSITION TERMINATED NO. 999999 |
| Monday, March 24, 2025 | TTAB RELEASE CASE TO TRADEMARKS |
| Tuesday, May 6, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, November 4, 2025 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 4, 2025 | SOU EXTENSION 1 FILED |
| Wednesday, November 5, 2025 | SOU EXTENSION 1 GRANTED |
| Wednesday, November 5, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |